LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Kodu・Aktsiate loetelu・SCYNEXIS Inc

SCYNEXIS Inc

Suletud

0.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.62

Max

0.64

Põhinäitajad
By Trading Economics
Sissetulek	-1.7M -8.6M
Müük	-1M 334K
Kasumimarginaal	-2,572.156
Töötajad	28
EBITDA	9.4M -186K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+438.46% upside

Turustatistika
By TradingEconomics
Turukapital	546K 27M
Eelmine avamishind	0.64
Eelmine sulgemishind	0.64

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

0.9307 / 0.9907 Toetus ja vastupanu

SCYNEXIS Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2025, 22:02 UTC

Tulu

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. dets 2025, 21:46 UTC

Tulu

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. dets 2025, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. dets 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. dets 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. dets 2025, 23:20 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. dets 2025, 23:15 UTC

Tulu

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. dets 2025, 22:59 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. dets 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. dets 2025, 22:40 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 22:06 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 22:02 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:00 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. dets 2025, 21:53 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. dets 2025, 21:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. dets 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 21:33 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. dets 2025, 21:32 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. dets 2025, 21:25 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. dets 2025, 21:16 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. dets 2025, 21:15 UTC

Tulu

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Võrdlus sarnastega

Hinnamuutus

SCYNEXIS Inc Prognoos

Hinnasiht

By TipRanks

438.46% tõus

12 kuu keskmine prognoos

Keskmine 3.5 USD 438.46%

Kõrge 4 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi SCYNEXIS Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi SCYNEXIS Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9307 / 0.9907Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.